John F. Paolini - 07 Nov 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
07 Nov 2022
Net transactions value
-$377,715
Form type
4
Filing time
09 Nov 2022, 15:16:08 UTC
Previous filing
06 Sep 2022
Next filing
20 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $52,744 +28,357 +78% $1.86* 64,692 07 Nov 2022 Direct F1
transaction KNSA Class A Common Share Sale $430,459 -28,357 -44% $15.18 36,335 07 Nov 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -28,357 -14% $0.000000 169,217 07 Nov 2022 Class A Common Share 28,357 $1.86 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $15.00 to $15.45. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 The option is fully vested and exercisable.